Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
microRNA-569 (miR-569) is a short, non-coding RNA molecule (20–24 nucleotides) involved in post-transcriptional gene regulation, primarily by binding to the 3'-untranslated regions of target mRNAs and affecting their stability or translation. miR-569 has been identified as a tumor suppressor in pancreatic cancer, where its expression is reduced in poor prognosis cases. Overexpression of miR-569 in cell and animal models suppresses tumor cell migration, invasion, and liver metastasis, primarily by directly targeting and downregulating NUSAP1, a spindle-associated protein, and consequently inhibiting the pro-metastatic ZEB1 pathway. Low levels of miR-569 are associated with poor survival in pancreatic cancer, and it may serve as both a prognostic biomarker and a potential therapeutic target. No direct drug or small-molecule modulators of miR-569 are currently known, but altering its activity or mimicking its function could be a potential therapeutic avenue for certain cancers[1][2][4].
Inhibits NUSAP1 mRNA/protein translation by direct binding to its 3'-untranslated region, leading to downstream effects on ZEB1 and metastatic processes.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on microRNA-569 (miR-569).